Stada's sales in the first six months of this year were hit by weakened currencies, particularly in Russia, Serbia and the UK, and fell by 8% to €755.2 million. Its earnings before interest, tax, depreciation and amortisation decreased by 16% to €124 million and net profit was down by more than 20% to €48.3 million. Earnings per share reduced from €1.07 in the first half of 2008 to €0.82.
Sales of generic products fell by 4% to €537.8 million, but they still accounted for more than 70% of Stada's...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
